1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis - Pipeline Review, H2 2020, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape.
Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer, depression, and severe dehydration. Common symptoms of ulcerative colitis include rectal bleeding, abdominal pain, and diarrhea. Treatment options for ulcerative colitis include surgery (removal of colon) or drug therapy with aminoasylates (ASA), immunomodulators, and corticosteroids.
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Ulcerative Colitis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Ulcerative Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Ulcerative Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 19, 60, 35, 6, 81 and 21 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 14 molecules, respectively.
Ulcerative Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Ulcerative Colitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Ulcerative Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ulcerative Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ulcerative Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ulcerative Colitis (Gastrointestinal)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ulcerative Colitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ulcerative Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Ulcerative Colitis - Overview
- Ulcerative Colitis - Therapeutics Development
- Ulcerative Colitis - Therapeutics Assessment
- Ulcerative Colitis - Companies Involved in Therapeutics Development
- Ulcerative Colitis - Drug Profiles
- Ulcerative Colitis - Dormant Projects
- Ulcerative Colitis - Discontinued Products
- Ulcerative Colitis - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Ulcerative Colitis, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Ulcerative Colitis - Pipeline by 9 Meters Biopharma Inc, H2 2020
- Ulcerative Colitis - Pipeline by AbbVie Inc, H2 2020
- Ulcerative Colitis - Pipeline by Abivax SA, H2 2020
- Ulcerative Colitis - Pipeline by Aclaris Therapeutics Inc, H2 2020
- Ulcerative Colitis - Pipeline by Affilogic SAS, H2 2020
- Ulcerative Colitis - Pipeline by Akebia Therapeutics Inc, H2 2020
- Ulcerative Colitis - Pipeline by Akeso Inc, H2 2020
- Ulcerative Colitis - Pipeline by Algernon Pharmaceuticals Inc, H2 2020
- Ulcerative Colitis - Pipeline by Alivio Therapeutics Inc, H2 2020
- Ulcerative Colitis - Pipeline by Allergan Ltd, H2 2020
- Ulcerative Colitis - Pipeline by Alpha Cancer Technologies Inc, H2 2020
- Ulcerative Colitis - Dormant Projects, H2 2020
- Ulcerative Colitis - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Ulcerative Colitis, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 9 Meters Biopharma Inc
- AbbVie Inc
- Abivax SA
- Aclaris Therapeutics Inc
- Affilogic SAS
- Akebia Therapeutics Inc
- Akeso Inc
- Algernon Pharmaceuticals Inc
- Alivio Therapeutics Inc
- Allergan Ltd
- Alpha Cancer Technologies Inc
- Circle33 LLC
- Exeliom Biosciences SAS
- F. Hoffmann-La Roche Ltd
- Ferring International Center SA
- Finch Therapeutics Group
- First Wave Bio Inc
- FYB202 GmbH & Co KG
- Fzata Inc
- Galapagos NV
- Genentech USA Inc
- Giiant Pharma Inc
- Gilead Sciences Inc
- GlaxoSmithKline Plc
- GLW Pharma
- Gossamer Bio Inc
- Guangzhou Magpie Pharmaceutical Co Ltd
- Hefei Cosource Pharmaceutical Inc
- Himuka AM Pharma Corp
- Holy Stone Healthcare Co Ltd
- Ichnos Sciences Inc
- Iltoo Pharma
- Immunic Inc
- Impetis Biosciences Ltd
- Inception Sciences Inc
- InDex Pharmaceuticals Holding AB
- Innovation Pharmaceuticals Inc
- Innovative Pharmacological Research (IPHAR) Co Ltd
- Innovent Biologics Inc
- Innovimmune Biotherapeutics Inc
- InSight Biopharmaceuticals Ltd
- Intact Therapeutics
- Intas Pharmaceuticals Ltd
- Intract Pharma Ltd
- Istesso Ltd
- Jiangsu Carephar Pharmaceutical Co Ltd
- Jiangsu Hengrui Medicine Co Ltd
- Johnson & Johnson
- Kaken Pharmaceutical Co Ltd
- Kaleido Biosciences Inc
- Kalytera Therapeutics Inc
- Kiniksa Pharmaceuticals Ltd
- Kintai Therapeutics Inc
- KoBioLabs Inc
- Korea Pharma Co Ltd
- Koutif Therapeutics LLC
- Landos Biopharma Inc
- LG Chem Ltd
- LIPID THERAPEUTICS GmbH
- LTT Bio-Pharma Co Ltd
- MAKScientific LLC
- Mesoblast Ltd
- Metacrine Inc
- Microbiotica Ltd
- Mitsubishi Tanabe Pharma Corp
- Morphic Holding Inc
- NeuClone Pty Ltd
- Nichi-Iko Pharmaceutical Co Ltd
- Novartis AG
- Nubiyota LLC
- Numedii Inc
- Nyrada Inc
- Oncodesign SA
- Oncostellae SL
- Oppilan Pharma Ltd
- OSE Immunotherapeutics
- Ovamed GmbH
- Palatin Technologies Inc
- Palo BioFarma SL
- Pandion Therapeutics Inc
- PanTheryx Inc
- Paradigm Biopharmaceuticals Ltd
- Pfizer Inc
- Pharmabiome AG
- Pharmapraxis
- Pharmaxis Ltd
- PNB Vesper Life Science Pvt Ltd
- Praeventix LLC
- Progenity Inc
- Prometheus Biosciences Inc
- Protab Ltd
- Protagonist Therapeutics Inc
- Protalix BioTherapeutics Inc
- Provention Bio Inc
- Qu Biologics Inc
- Re-Pharm Ltd
- Rebiotix Inc
- Regentys Corp
- RhemaStem SRLS
- Rhizen Pharmaceuticals SA
- Salix Pharmaceuticals Ltd
- Saniona AB
- Santhera Pharmaceuticals Holding AG
- Sareum Holdings Plc
- Semorex Technologies Ltd
- Seres Therapeutics Inc
- Servatus Ltd
- Shaperon Inc
- Siam Bioscience Co Ltd
- StemRIM Inc
- sterna biologicals Gmbh & Co KG
- Sublimity Therapeutics HoldCo Ltd
- Surrozen Inc
- Suzhou Connect Biopharmaceuticals Ltd
- Swedish Orphan Biovitrum AB
- Synedgen Inc
- Synlogic Inc
- Takeda Pharmaceutical Co Ltd
- Tarus Therapeutics Inc
- TheraSource LLC
- Theravance Biopharma Inc
- Thetis Pharmaceuticals LLC
- Tianjin Hemay Pharmaceutical Co Ltd
- Tillotts Pharma AG
- TopiVert Ltd
- Torrent Pharmaceuticals Ltd
- Ventria Bioscience
- Vivreon Biosciences LLC
- Voronoi Group
- Zhiyi Pharmaceuticals Inc
